-
-
-
-
-
-
-
Harmony Biosciences forecasts WAKIX revenue to exceed $1 billion in 2026
-
-
-
-
-
-
-
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
-
-
-
-
-
-
-
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
-
-
-
-
-
-
-
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Acquires Epygenix Therapeutics, Inc.
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Announces FDA Grants Priority Review for Application For Wakix (Pitolisant) In Pediatric Narcolepsy
-
1,160,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

